A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties*

Thiazolidinediones (TZDs) constitute an exciting new class of antidiabetic compounds, which function as activating ligands for peroxisome proliferator-activated receptor γ (PPARγ). Until now, there has been an excellent correlation between in vivo hypoglycemic potency and in vitro binding and activation of PPARγ by TZDs. We have characterized MCC-555, a novel thiazolidinedione ligand for PPARγ with unique functional properties. The antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity for PPARγ is less than 1 10 that of BRL49653. The effect of MCC-555 binding on PPARγ transcriptional activity is highly context-specific such that it can function as a full agonist, partial agonist, or antagonist depending on the cell type or DNA binding site. These transcriptional properties are partly explained by unique partial agonism of coactivator recruitment to PPARγ. The properties of MCC-555 are mechanistically distinct from those of the estrogen receptor partial agonist and antagonist tamoxifen because the N terminus of PPARγ is not required for activation by MCC-555, and MCC-555 does not stimulate corepressor recruitment to PPARγ. The context selectivity of MCC-555 may contribute to its enhanced hypoglycemic potency in vivodespite reduced affinity for PPARγ relative to other TZDs.

[1]  B. Spiegelman,et al.  Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. , 1997, The Journal of clinical investigation.

[2]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[3]  M. Lazar,et al.  Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression , 1997, Molecular and cellular biology.

[4]  C. Glass,et al.  Nuclear receptor coactivators. , 1997, Current opinion in cell biology.

[5]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[6]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[7]  M. Lazar,et al.  Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Auwerx,et al.  Coordinate Regulation of the Expression of the Fatty Acid Transport Protein and Acyl-CoA Synthetase Genes by PPARα and PPARγ Activators* , 1997, The Journal of Biological Chemistry.

[9]  S. Minucci,et al.  The histone acetylase PCAF is a nuclear receptor coactivator. , 1998, Genes & development.

[10]  Margaret S. Wu,et al.  Down-regulation of the Expression of the Obese Gene by an Antidiabetic Thiazolidinedione in Zucker Diabetic Fatty Rats and db/db Mice (*) , 1996, The Journal of Biological Chemistry.

[11]  P G Pelicci,et al.  Genetics of APL and the molecular basis of retinoic acid treatment , 1997, International journal of cancer.

[12]  R. Ulrich,et al.  Enhancement of adipocyte differentiation by an insulin-sensitizing agent. , 1992, Molecular pharmacology.

[13]  M. Lazar,et al.  direct repeat . represses transcription as a dimer on a novel The monomer-binding orphan receptor RevErb , 1995 .

[14]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[15]  B. Spiegelman,et al.  Functional Antagonism between CCAAT/Enhancer Binding Protein-α and Peroxisome Proliferator-activated Receptor-γ on the Leptin Promoter* , 1997, The Journal of Biological Chemistry.

[16]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[17]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[18]  J. Auwerx,et al.  Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. , 1996, The Journal of clinical investigation.

[19]  M. Lazar,et al.  Transcriptional Activation by Peroxisome Proliferator-activated Receptor γ Is Inhibited by Phosphorylation at a Consensus Mitogen-activated Protein Kinase Site* , 1997, The Journal of Biological Chemistry.

[20]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[21]  M. Imhof,et al.  Cellular Mechanisms Which Distinguish between Hormone‐ and Antihormone‐Activated Estrogen Receptor , 1995, Annals of the New York Academy of Sciences.

[22]  S. Mudaliar,et al.  PPAR-γ Gene Expression Is Elevated in Skeletal Muscle of Obese and Type II Diabetic Subjects , 1997, Diabetes.

[23]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[24]  P. Chambon,et al.  Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors (mediators). , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[25]  M. Lazar,et al.  Peroxisome Proliferator Activated Receptor γ, CCAAT/ Enhancer-binding Protein α, and Cell Cycle Status Regulate the Commitment to Adipocyte Differentiation* , 1997, The Journal of Biological Chemistry.

[26]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[27]  J. Lehmann,et al.  The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones , 1996 .

[28]  M. Lazar,et al.  Induction of Rev-ErbA alpha, an orphan receptor encoded on the opposite strand of the alpha-thyroid hormone receptor gene, during adipocyte differentiation. , 1993, The Journal of biological chemistry.

[29]  M. Lazar,et al.  Stoichiometric and steric principles governing repression by nuclear hormone receptors. , 1997, Genes & development.

[30]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[31]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[32]  R. Weiss,et al.  The syndromes of resistance to thyroid hormone. , 1993, Endocrine reviews.

[33]  K.,et al.  Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. Parker,et al.  Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Neal,et al.  Basic science aspects of prostate cancer. , 1997, Seminars in cancer biology.

[36]  C. Glass,et al.  Transcription factor-specific requirements for coactivators and their acetyltransferase functions. , 1998, Science.